Roxadustat (FG-4592) Versus Epoetin Alfa for Anemia in Patients Receiving Maintenance Hemodialysis: A Phase 2, Randomized, 6- to 19-Week, Open-Label, Active-Comparator, Dose-Ranging, Safety and Exploratory Efficacy Study.

R, Provenzano; A, Besarab; S, Wright; S, Dua; S, Zeig; P, Nguyen; L, Poole; KG, Saikali; G, Saha; S, Hemmerich; L, Szczech; KH, Yu; TB, Neff

doi:10.1053/j.ajkd.2015.12.020

Public

Roxadustat (FG-4592) Versus Epoetin Alfa for Anemia in Patients Receiving Maintenance Hemodialysis: A Phase 2, Randomized, 6- to 19-Week, Open-Label, Active-Comparator, Dose-Ranging, Safety and Exploratory Efficacy Study.

Shared by NobleBlocks on Feb 2, 2016 • 12:00 AM UTC

Authors:

Provenzano R

Besarab A

Wright S

Abstract

Background Roxadustat (FG-4592) is an oral hypoxia-inducible factor prolyl-hydroxylase inhibitor that promotes erythropoiesis through increasing endogenous erythropoietin, improving iron regulation, and reducing hepcidin.Study design Phase 2, randomized (3:1), open-label, active-comparator, safety a...

Subject

Anemia

Erythropoietin

Hemoglobin (Hb)

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!